ArticleThe Journal of allergy and clinical immunology2019
New insights into the utility of omalizumab.
Article in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.Nature medicine · 2025Trial
- Anti-DENV IgE correlates with dengue severity and triggers FcεRI-dependent basophil activation inhibited by Omalizumab.Scientific reports · 2026Article
- Evaluating stapokibart in the treatment of seasonal allergic rhinitis.Immunotherapy · 2025Review
- Observational
- Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial.Frontiers in medicine · 2024Article
- The effect of COVID-19 on patients recieving omalizumab treatment.Revue francaise d'allergologie (2009) · 2023Article
- Omalizumab may protect allergic patients against COVID-19: A systematic review.The World Allergy Organization journal · 2023Review
- Management of IgE-mediated food allergy in the 21st century.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023Review
- The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment.Revue francaise d'allergologie (2009) · 2022Article
- ERS International Virtual Congress 2021: Highlights from the Turkish Thoracic Society Early Career Members.Turkish thoracic journal · 2022Article
- Immunoglobulin E-Dependent Activation of Immune Cells in Rhinovirus-Induced Asthma Exacerbation.Frontiers in allergy · 2022Article
- Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective.Children (Basel, Switzerland) · 2021Review
- Pediatric usage of Omalizumab: A promising one.The World Allergy Organization journal · 2021Review
- [In vitro study on the individual binding ability of omalizumab with free IgE].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021Article
- Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab.Biomedicines · 2021Review
- A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation.Mucosal immunology · 2021Article
- Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.Frontiers in immunology · 2021Article
- Prevention of Asthma: Targets for Intervention.Chest · 2020Review
- Immunomodulation in Pediatric Asthma.Frontiers in pediatrics · 2019Review
Corrections and comments
- Commented on byReply.2019
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.